Tasigna (nilotinib) capsule
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
Clinical Trials Experience
- Table 5: Most Frequently Reported Non-hematologic Adverse Reactions (Regardless of Relationship to Study Drug) in Patients with Newly Diagnosed Ph+ CML-CP (≥10% in Tasigna 300 mg twice daily or Imatinib 400 mg once daily groups) 36-Month Analysisa…
- peripheral arterial occlusive disease
WARNINGS AND PRECAUTIONS
Tumor Lysis Sydrome
- added ... new section; moved from Adverse Reactions, Postmarketing experience
"What are the possible side effects...?"
- updated to include tumor lysis syndrome
5 WARNINGS AND PRECAUTIONS
5.3 Sudden Deaths
- Sudden deaths have been reported in patients with CML treated with nilotinib in clinical studies (n=5,661; 0.3%). The relative early occurrence of some of these deaths relative to the initiation of nilotinib suggests the possibility that ventricular repolarization abnormalities may have contributed to their occurrence.
5.8 Food Effects
- Patients should avoid food…..
6 ADVERSE REACTIONS
6.1 Clinical Trial Experience
6.2 Additional Data from Clinical Trials
- Changes to Infections and Infestations, Endocrine Disorders, General Disorders and Administration Site Conditions, and Investigations sections
- Reflects new, updated dosing information concerning mixing the contents of the capsules with applesauce (see Medication Guide for specifics)
Also see changes to Dosage and administration: Recommended Dosing (2.1)
Effects of Nilotinib on Drug Metabolizing Enzymes and Drug Transport Systems
- Single-dose administration of Tasigna with midazolam (a CYP3A4 substrate) to healthy subjects increased midazolam exposure by 30%.
Drugs that Affect Gastric pH
- Nilotinib has pH-dependent solubility, with decreased solubility at higher pH. Drugs such as proton pump inhibitors that inhibit gastric acid secretion to elevate the gastric pH may decrease the solubility of nilotinib and reduce its bioavailability. In healthy subjects, coadministration of a single 400 mg dose of Tasigna with multiple doses of esomeprazole (a proton pump inhibitor) at 40 mg daily decreased the nilotinib AUC by 34%. Increasing the dose of Tasigna when co-administered with such agents is not likely to compensate for the loss of exposure. Since proton pump inhibitors affect pH of the upper GI tract for an extended period, separation of doses may not eliminate the interaction. The concomitant use of proton pump inhibitors with Tasigna should be used with caution.